510 related articles for article (PubMed ID: 22526360)
41. Impaired expression of indoleamine 2, 3-dioxygenase in monocyte-derived dendritic cells in response to Toll-like receptor-7/8 ligands.
Furset G; Fløisand Y; Sioud M
Immunology; 2008 Feb; 123(2):263-71. PubMed ID: 17725606
[TBL] [Abstract][Full Text] [Related]
42. Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites.
Terness P; Bauer TM; Röse L; Dufter C; Watzlik A; Simon H; Opelz G
J Exp Med; 2002 Aug; 196(4):447-57. PubMed ID: 12186837
[TBL] [Abstract][Full Text] [Related]
43. Novel role of plasmacytoid dendritic cells in humans: induction of interleukin-10-producing Treg cells by plasmacytoid dendritic cells in patients with rheumatoid arthritis responding to therapy.
Kavousanaki M; Makrigiannakis A; Boumpas D; Verginis P
Arthritis Rheum; 2010 Jan; 62(1):53-63. PubMed ID: 20039433
[TBL] [Abstract][Full Text] [Related]
44. Normal development and function of dendritic cells in mice lacking IDO-1 expression.
de Faudeur G; de Trez C; Muraille E; Leo O
Immunol Lett; 2008 Jun; 118(1):21-9. PubMed ID: 18384884
[TBL] [Abstract][Full Text] [Related]
45. Human myeloid dendritic cells are refractory to tryptophan metabolites.
von Bubnoff D; Wilms H; Scheler M; Brenk M; Koch S; Bieber T
Hum Immunol; 2011 Oct; 72(10):791-7. PubMed ID: 21699942
[TBL] [Abstract][Full Text] [Related]
46. Indoleamine 2,3-dioxygenase gene transfer prolongs cardiac allograft survival.
Li J; Meinhardt A; Roehrich ME; Golshayan D; Dudler J; Pagnotta M; Trucco M; Vassalli G
Am J Physiol Heart Circ Physiol; 2007 Dec; 293(6):H3415-23. PubMed ID: 17933973
[TBL] [Abstract][Full Text] [Related]
47. Indoleamine 2,3-dioxygenase-expressing dendritic cells are involved in the generation of CD4+CD25+ regulatory T cells in Peyer's patches in an orally tolerized, collagen-induced arthritis mouse model.
Park MJ; Min SY; Park KS; Cho YG; Cho ML; Jung YO; Park HS; Chang SH; Cho SG; Min JK; Park SH; Kim HY
Arthritis Res Ther; 2008; 10(1):R11. PubMed ID: 18221522
[TBL] [Abstract][Full Text] [Related]
48. CDllc+ cells modulate pulmonary immune responses by production of indoleamine 2,3-dioxygenase.
Swanson KA; Zheng Y; Heidler KM; Mizobuchi T; Wilkes DS
Am J Respir Cell Mol Biol; 2004 Mar; 30(3):311-8. PubMed ID: 12959949
[TBL] [Abstract][Full Text] [Related]
49. Human type 1 and type 2 conventional dendritic cells express indoleamine 2,3-dioxygenase 1 with functional effects on T cell priming.
Sittig SP; van Beek JJP; Flórez-Grau G; Weiden J; Buschow SI; van der Net MC; van Slooten R; Verbeek MM; Geurtz PBH; Textor J; Figdor CG; de Vries IJM; Schreibelt G
Eur J Immunol; 2021 Jun; 51(6):1494-1504. PubMed ID: 33675038
[TBL] [Abstract][Full Text] [Related]
50. Ligation of B7-1/B7-2 by human CD4+ T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells.
Munn DH; Sharma MD; Mellor AL
J Immunol; 2004 Apr; 172(7):4100-10. PubMed ID: 15034022
[TBL] [Abstract][Full Text] [Related]
51. Association of enhanced activity of indoleamine 2,3-dioxygenase in dendritic cells with the induction of regulatory T cells in chronic hepatitis C infection.
Higashitani K; Kanto T; Kuroda S; Yoshio S; Matsubara T; Kakita N; Oze T; Miyazaki M; Sakakibara M; Hiramatsu N; Mita E; Imai Y; Kasahara A; Okuno A; Takikawa O; Hayashi N; Takehara T
J Gastroenterol; 2013 May; 48(5):660-70. PubMed ID: 22976933
[TBL] [Abstract][Full Text] [Related]
52. Increased Expression of Indoleamine 2,3-Dioxygenase (IDO) in Vogt-Koyanagi-Harada (VKH) Disease May Lead to a Shift of T Cell Responses Toward a Treg Population.
Zhang L; Huang Y; Cui X; Tan X; Zhu Y; Zhou W; Wang C; Yuan G; Cao Q; Su G; Kijlstra A; Yang P
Inflammation; 2020 Oct; 43(5):1780-1788. PubMed ID: 32435912
[TBL] [Abstract][Full Text] [Related]
53. Decreased expression of indoleamine 2,3-dioxygenase 1 in dendritic cells contributes to impaired regulatory T cell development in immune thrombocytopenia.
Catani L; Sollazzo D; Trabanelli S; Curti A; Evangelisti C; Polverelli N; Palandri F; Baccarani M; Vianelli N; Lemoli RM
Ann Hematol; 2013 Jan; 92(1):67-78. PubMed ID: 22936460
[TBL] [Abstract][Full Text] [Related]
54. Antigen-specific T cell functions are suppressed over the estrogen-dendritic cell-indoleamine 2,3-dioxygenase axis.
Xiao BG; Liu X; Link H
Steroids; 2004 Sep; 69(10):653-9. PubMed ID: 15465110
[TBL] [Abstract][Full Text] [Related]
55. Silencing of indoleamine 2,3-dioxygenase enhances dendritic cell immunogenicity and antitumour immunity in cancer patients.
Sioud M; Saebøe-Larssen S; Hetland TE; Kaern J; Mobergslien A; Kvalheim G
Int J Oncol; 2013 Jul; 43(1):280-8. PubMed ID: 23620105
[TBL] [Abstract][Full Text] [Related]
56. CTLA-4-mediated regulatory phenotype of T-cells in tolerant lung recipients.
Botturi K; Lacoeuille Y; Thomas P; Boniface S; Reynaud-Gaubert M; Magnan A
Eur Respir J; 2008 Jun; 31(6):1167-76. PubMed ID: 18256061
[TBL] [Abstract][Full Text] [Related]
57. SOCS3 drives proteasomal degradation of indoleamine 2,3-dioxygenase (IDO) and antagonizes IDO-dependent tolerogenesis.
Orabona C; Pallotta MT; Volpi C; Fallarino F; Vacca C; Bianchi R; Belladonna ML; Fioretti MC; Grohmann U; Puccetti P
Proc Natl Acad Sci U S A; 2008 Dec; 105(52):20828-33. PubMed ID: 19088199
[TBL] [Abstract][Full Text] [Related]
58. [Research Progress on role of Abnormal Tryptophan Metabolism in Immune Thrombocytopenia].
Li ZJ; Liu XQ; Xu JQ; Chu XX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Dec; 23(6):1813-6. PubMed ID: 26708916
[TBL] [Abstract][Full Text] [Related]
59. Human CD14+ CTLA-4+ regulatory dendritic cells suppress T-cell response by cytotoxic T-lymphocyte antigen-4-dependent IL-10 and indoleamine-2,3-dioxygenase production in hepatocellular carcinoma.
Han Y; Chen Z; Yang Y; Jiang Z; Gu Y; Liu Y; Lin C; Pan Z; Yu Y; Jiang M; Zhou W; Cao X
Hepatology; 2014 Feb; 59(2):567-79. PubMed ID: 23960017
[TBL] [Abstract][Full Text] [Related]
60. The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells.
Jochems C; Fantini M; Fernando RI; Kwilas AR; Donahue RN; Lepone LM; Grenga I; Kim YS; Brechbiel MW; Gulley JL; Madan RA; Heery CR; Hodge JW; Newton R; Schlom J; Tsang KY
Oncotarget; 2016 Jun; 7(25):37762-37772. PubMed ID: 27192116
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
